4 articles
The FDA approved Revolution Medicines' Rasonque for metastatic pancreatic cancer, boosting median survival to 13.2 months versus 6.7 months on standard therapy. This first-in-class RAS inhibitor addre
Revolution Medicines' experimental drug daraxonrasib nearly doubled survival time for advanced pancreatic cancer patients compared to chemotherapy. The FDA plans to expedite review as researchers hail
Geopolitical tensions drove Brent crude prices above $94, while Nvidia unveiled new AI chips boosting semiconductor demand. Additionally, Revolution Medicines saw shares surge after successful pancrea
Revolution Medicines chemist Jim Cregg discusses his work targeting the undruggable KRas protein following the company's acquisition of Warp Drive Bio. His research focuses on developing small molecul
ChemBrief